Home › Funds › BROOKTREE CAPITAL MANAGEMENT › ABT

BROOKTREE CAPITAL MANAGEMENT position in ABT

ABBOTT LABORATORIES · Health Care

BROOKTREE CAPITAL MANAGEMENT reported holding 4,984 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$493K, representing 0.34% of its reported portfolio and ranking #32 among its reported holdings. BROOKTREE CAPITAL MANAGEMENT has disclosed ABT holdings in 8 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)4.98K sh
Reported value held$492.57K
Portfolio Weight0.34%
First reportedQ3 2023
Last changeHold
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How BROOKTREE CAPITAL MANAGEMENT's ABT position evolved

BROOKTREE CAPITAL MANAGEMENT first disclosed a stake in ABT in Q3 2023 at 2,661 shares (US$258K). The position peaked in Q2 2025 at 5,100 shares, worth US$694K. Across 8 filings, BROOKTREE CAPITAL MANAGEMENT increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 4,984 shares valued at US$493K.

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.66K $257.72K New
Q4 2023 2.64K $291.02K Reduce
Q2 2025 5.10K $693.65K New
Q3 2025 5.10K $683.09K Hold
Q4 2025 5.10K $638.98K Hold
Q1 2026 4.98K $511.71K Reduce
Q2 2026 4.98K $452.25K Hold
Q3 2026 4.98K $492.57K Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has BROOKTREE CAPITAL MANAGEMENT held ABT?

BROOKTREE CAPITAL MANAGEMENT has disclosed ABT holdings in 8 of the last 13 reported quarters, going back to Q3 2023.

What is BROOKTREE CAPITAL MANAGEMENT's current position in ABT?

As of Q3 2026, BROOKTREE CAPITAL MANAGEMENT holds 4.98K shares of ABT (ABBOTT LABORATORIES), valued at $492.57K, representing 0.34% of its reported portfolio and ranking #32.

Has BROOKTREE CAPITAL MANAGEMENT been buying or selling ABT?

In the latest 13F filing (Q3 2026), BROOKTREE CAPITAL MANAGEMENT held unchanged its position in ABT. The position peaked in Q2 2025 at 5.10K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.